Back to top

Image: Bigstock

GW Pharmaceuticals plc

Read MoreHide Full Article

GW Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of cannabinoid-based drugs. GW Pharma’s fiscal third quarter 2015 earnings were wider than expected. The company’s key growth driver, Sativex, is marketed in 27 countries outside the U.S. for the treatment of spasticity due to multiple sclerosis. We are positive on the company’s efforts to expand Sativex’s label. Progress of the company’s late-stage candidate, Epidiolex, looks impressive. However, GW Pharma’s drugs may face competition from other cannabinoid-based treatments available in the over-the-counter market. Additionally, the company relies heavily on Sativex for growth, which is concerning.